Methods: Among a total of 257 patients who received treatment for hepatolithiasis, 236 patients were eligible for analysis. 92 patients underwent liver resection (resection group) and 144 patients did not (non-resection group). The data was collected retrospectively and analyzed. Results: The incidence of cholangiocarcinoma was 6.8% (16/236) during follow-up period (mean 41 ± 41 months). Cholangiocarcinoma occurred 6.3% (6/95) and 7.1% learn more (10/141) in resection and non-resection group respectively (p = 0.263). When analyzed according to completeness of stone removal regardless of treatment modality, Cholangiocarcinoma incidence

was higher in patients with residual stone(10.4%) than patients with complete stone removal (3.3%), but there was no significant difference (p = 0.263). On univariate analysis, none of the factors (age, gender, CA19-9, stone location, bile duct stenosis, liver atrophy, stone recurrence and liver resection) showed relationship with the incidence of cholangiocarcinoma. Conclusion: Hepatic resection

for hepatolithiasis is considered to have a limited value in preventing of cholangiocarcinoma and the patients should be carefully followed even after hepatic resection. A combination of different treatment modalities is necessary to decrease the residual stone and improve the outcome of the patients with hepatolithiasis. Key Word(s): 1. cholangiocarcinoma; 2. hepatolithiasis; Adriamycin 3. hepatic

resection Presenting Author: TAE NYEUN KIM Additional Authors: SUNG BUM KIM, KOOK HYUN KIM, KYEONG OK KIM, SI HYUNG LEE, BYUNG IK JANG Corresponding Author: TAE NYEUN KIM Affiliations: Yeungnam University College of Medicine, Yeungnam University College of Medicine, Yeungnam University College of Medicine, Yeungnam University College of Medicine, Yeungnam University College of Medicine Objective: 50–55% of CBD stone patients without symptom at present may experience symptoms or complication related to CBD Etofibrate stone in the future. Studies about risk of performing ERCP in asymptomatic CBD stone patients has been scarce. The aim of our study was to compare ERCP complication rate between asymptomatic and symptomatic CBD stone patients. Methods: Patients diagnosed as CBD stone and underwent ERCP from Jan 2010 to Dec 2013 were included and their clinical data were collected and analyzed retrospectively. Patients without symptom associated with CBD stone were classified as asymptomatic group and with symptom as symptomatic group. Results: Among 323 patients with CBD stone, 306 patients had symptomatic CBD stone and 17 patients, asymptomatic CBD stone. Mean age of asymptomatic and symptomatic group was 68.2 ± 12.9 and 64.7 ± 17.0, respectively (p = 0.442) and male proportion was not significantly different between both groups (64.7% vs 50.3%, p = 0.248).